Lupusnephritis

Schreiber, J; Eisenberger, Ute; Groot, Kirsten de

doi:10.1007/s00108-019-0574-y

Cited by 12 publications

(8 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kidney involvement (lupus nephritis) is the most common and in 25 % of cases it is the first manifestation of SLE in solid organs [53]. However, the first symptoms of renal injury often only appear late in its clinical course.…”

Section: Lupus Nephritismentioning

confidence: 99%

Pr-AKI: Acute Kidney Injury in Pregnancy – Etiology, Diagnostic Workup, Management

Scurt

Morgenroth

Bose

et al. 2022

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

Despite significant improvements in inpatient and outpatient management, pregnancy-related acute kidney injury (Pr-AKI) remains an important risk factor for early and late maternal and fetal morbidity and mortality. There is a discrepancy between the incidence of Pr-AKI in developing and in developed countries, with the former experiencing a decrease and the latter an increase in Pr-AKI in recent decades. Whereas septic and hemorrhagic complications predominated in the past, nowadays hypertensive disorders and thrombotic microangiopathy are the leading causes of Pr-AKI. Modern lifestyles and the availability and widespread use of in-vitro fertilization techniques in industrialized countries have allowed more women of advanced age to become pregnant. This has led to a rise in the percentage of high-risk pregnancies due to the disorders and comorbidities inherent to or accompanying aging, such as diabetes, arterial hypertension and preexisting chronic kidney disease. Last but not least, the heterogeneity of symptoms, the often overlapping clinical and laboratory characteristics and the pathophysiological changes related to pregnancy make the diagnosis and management of Pr-AKI a difficult and challenging task for the treating physician. In addition to general supportive management strategies such as volume substitution, blood pressure control, prevention of seizures or immediate delivery, each disease entity requires a specific therapy to reduce maternal and fetal complications. In this review, we used the current literature to provide a summary of the physiologic and pathophysiologic changes in renal physiology which occur during pregnancy. In the second part, we present common and rare disorders which lead to Pr-AKI and provide an overview of the available treatment options.

show abstract

Section: Lupus Nephritismentioning

confidence: 99%

Pr-AKI: Acute Kidney Injury in Pregnancy – Etiology, Diagnostic Workup, Management

Scurt

Morgenroth

Bose

et al. 2022

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

show abstract

“…Lupus nephritis is a severe complication of SLE in which the accumulation of immune complexes plays a key role [ 28 ]. LN can occur in several clinical presentations, from asymptomatic forms to rapidly progressive kidney disease, which correspond to different histological classes of lupus nephritis (LN) [ 29 , 30 , 31 ]. In addition, patients with LN are prone to present hypertension, renal failure and infections in earlier stages of the disease, among other complications [ 26 , 30 ].…”

Section: Characteristics Of Lupus Nephritismentioning

confidence: 99%

Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis

Rafael-Vidal

Altabás

Pérez

et al. 2021

IJMS

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a broad spectrum of clinical presentations that can affect almost all organ systems. Lupus nephritis (LN) is a severe complication that affects approximately half of the systemic erythematosus lupus (SLE) patients, which significantly increases the morbidity and the mortality risk. LN is characterized by the accumulation of immune complexes, ultimately leading to renal failure. Aberrant activation of T cells plays a critical role in the pathogenesis of both SLE and LN and is involved in the production of inflammatory cytokines, the recruitment of inflammatory cells to the affected tissues and the co-stimulation of B cells. Calcineurin is a serine-threonine phosphatase that, as a consequence of the T cell hyperactivation, induces the production of inflammatory mediators. Moreover, calcineurin is also involved in the alterations of the podocyte phenotype, which contribute to proteinuria and kidney damage observed in LN patients. Therefore, calcineurin inhibitors have been postulated as a potential treatment strategy in LN, since they reduce T cell activation and promote podocyte cytoskeleton stabilization, both being key aspects in the development of LN. Here, we review the role of calcineurin in SLE and the latest findings about calcineurin inhibitors and their mechanisms of action in the treatment of LN.

show abstract

“…Lupus nephritis (LN) is one of the most common and devastating manifestations of the chronic autoimmune disease systemic lupus erythematosus (SLE) (1). LN usually appears at least 3 years after the onset of SLE (2). SLE patients can pathologically form anti-double-stranded DNA immune complexes and deposit them onto regions of the kidney, and as a consequence, inflammatory responses and the subsequent chain reactions of abnormal and destructive immune activities can be generated, leading to irreversible kidney injury (1).…”

Section: Introductionmentioning

confidence: 99%

Taurine attenuates the damage of lupus nephritis mouse via inactivation of the NF-κB pathway

Luo¹,

Geng

Miao

et al. 2021

Ann Palliat Med

View full text Add to dashboard Cite

Background: Taurine is an organic amino acid and a major constituent of bile. With its contribution to various cellular functions, it has demonstrated therapeutic effects in a wide range of diseases. Since there is a lack of literature investigating taurine as a treatment for lupus nephritis (LN), here we examined the potential of taurine as a treatment for LN.Methods: Experiments were carried out using MRL/lpr mice as a model of LN, and C57BL/6 mice were used as negative controls. At 12 weeks old, MRL/lpr mice were divided into four groups and treated with 0, 50 and 100 mg/kg body weight taurine for 5 days. Enalapril is used as a positive control drug. All animals were sacrificed after treatment. LN-induced damage was assessed by proteinuria, blood urea nitrogen (BUN) and serum creatinine (CRE) levels. The degree of inflammation was assessed by inducible nitric oxide synthase (iNOS), interleukin-4 (IL-4), IL-10, and tumor necrosis factor-α (TNF-α) levels. The degree of oxidative stress was assessed by malondialdehyde (MDA), reactive oxygen species (ROS), superoxide dismutase (SOD), and glutathione peroxidase (Gpx) levels. Hematoxylin and eosin (HE) staining and TUNEL staining assessed histopathological damage and apoptosis, respectively. The levels of Bcl-2, Bax, caspase-3, caspase-9, and NF-κB p65 were detected by western blot.Results: The data indicated that taurine administration improved kidney functions, reversed cell death, suppressed oxidative stress, and importantly, adjusted the immune response of LN mice to a more balanced state.Conclusions: These results provide a novel strategy for LN therapy, which may overcome the disadvantages of traditional immunosuppression and hormone treatments with greater efficacy and fewer side effects.

show abstract

Lupusnephritis

Cited by 12 publications

References 41 publications

Pr-AKI: Acute Kidney Injury in Pregnancy – Etiology, Diagnostic Workup, Management

Pr-AKI: Acute Kidney Injury in Pregnancy – Etiology, Diagnostic Workup, Management

Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis

Taurine attenuates the damage of lupus nephritis mouse via inactivation of the NF-κB pathway

Contact Info

Product

Resources

About